“Volatility Holding” – Vista Partners Daily Market Recap 12/10/18

The market scored a “moral victory” on Monday according to Bespoke Investment Group as all three major indices rallied to end the day in the green. After spending much of the day in the red, the S&P 500 was up 0.18% (4.64 points) by the end of trading and the Dow finished with gains of 0.14% (34.31 points). The Nasdaq did the best of the three, rising 0.74% (51.27 points). However, what was consistent from our point of view & for anyone actively watching/investing/trading the market, was that it was a wild market with high volatility that seemed to continue to be fueled by increasing anxiety, uncertain worldwide headlines (trade wars, interest rates, oil, etc.) and algorithmic trading.

After last weeks volatility, Oliver Jones with Capital Economics believes that the same volatile pattern could hold for much of next year. “We think that [last] week’s turbulence provides a reasonable guide to the trends to watch for in the markets next year. In particular, while both the S&P 500 and U.S. Treasury yields have started to drop a little sooner than we had previously anticipated, we still suspect that both have much further to fall in 2019.

Of the Dow’s components, Microsoft (MSFT) was the biggest winner with an increase of 2.64%. Intel (INTC) also did well during today’s session, ending up 2.10% by the market’s closed. On the other hand, JPMorgan (JPM) saw the biggest losses with a decline of 1.87%.

Outside of the Dow, Atossa Genetics (ATOS) saw shares drop 3.79%.

On the other side of the coin, a bet, trade or investment in the VelocityShares Daily 2x VIX ST ETN (TVIX) realized a swing as high as $58.49 & a low of $51.26 before settling in at $52.51.  A wild ride!

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

Monday was a ‘moral victory’ for investors

Markets rebounded from early losses to close in the green on Monday but the market still remains in an overall downtrend and the pattern continues to be discouraging for investors…

finance.yahoo.com

Read Full Article



“Vista’s View – A Weekly FREE Market Update 12-8-18″…Now Available!

Vista Partners has published “Vista’s View – A Weekly Market Update Newsletter 12-8-18!”  

Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink.   Vista’s View includes an exclusive view on the stock market for the week, a “Stocks To Watch” section, featured stories that span from the Dow 30, select emerging growth companies, investing basics & exciting videos from Vista’s Coverage Universe and beyond.

Vista Covers all Dow 30 components, International Companies, Select Emerging Growth Companies & more on the website daily.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page Now.  It’s FREE!!!

Stay Informed! Stay Competitive!  Receive our FREE email updates by signing up today in just  few seconds!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




“Contrasts” – Vista Partners Daily Market Recap 12/7/2018

Several contrasts emerged on Friday, the first being between plunging stocks and soaring oil prices after OPEC agreed to slash its output by 1.2 million barrels per day. After opening with gains, stocks quickly slid with the S&P 500 ending down 2.33% (62.87 points) and the Nasdaq falling 3.05% (219.01 points). The Dow also performed poorly, as it plummeted 2.24% to end the session.

Individually, components of the Dow were down across the board, with every company in the index reporting losses. Intel (INTC) suffered the worst losses as it saw shares decrease 4.40%. Cisco (CSCO) wasn’t too far behind with a fall of 4.03%, and Microsoft (MSFT) rounded out the bottom three as it tumble 4.00%.

Atossa Genetics (ATOS) managed to buck the trend and end the day with gains of 1.54%.

An investment in the leveraged vehicle,  VelocityShares Daily 2x VIX ST ETN (TVIX) or the TVIX a many call it, produced another amazing day with a 14.70% increase on Friday!

The second contrast apparent today was between the volatility of the markets and the generally solid economic data. The jobs report for November showed that job growth was positive for the month but under economists’ predictions, and it showed that unemployment had held steady at 3.7%.

Paul Ashworth of Capital Economics had this to say about the apparent contrast. “The slightly more modest 155,000 gain…is still a solid gain that suggests economic growth is gradually slowing back toward its potential pace. There is nothing here to suggest the economy is suffering a more sudden downturn.”

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

Stocks tumble, crude oil surges on OPEC deal

Stock got slammed on Friday, and crude oil surged on an OPEC deal…

finance.yahoo.com

Read Full Article



“Free Falling” – Vista Partners Daily Market Recap 12/4/2018

After a strong showing yesterday, the market was in a free fall on Tuesday as stocks went crashing. The S&P 500 shed 3.24% during today’s session while the Nasdaq plummeted 3.80%. The Dow plunged 3.10% as the market closed.

Individual components of the Dow were down across the board, with every single company ending the day in the red. Caterpillar (CAT) led declines with a loss of 6.93%. Other companies seeing heavy losses include Boeing (BA), with a drop of 4.85%, and Intel (INTC), which sank 4.75%.

Outside the Dow, Atossa Genetics (ATOS) didn’t fare much better. It dropped 2.90% during today’s session after impressive gains yesterday.

On the other side of the coin a bet, trade on investment in the VelocityShares Daily 2x VIX ST ETN (TVIX), a “bet against the broad markets,” paid off handsomely today as it closed at $44.47 up +25.13% on the day! Thank you triggered algorythmic trades!

Two major factors are being blamed for today’s sudden downturn. The first was yesterday’s inversion of the 3-year and 5-year notes, a warning sign pointing to a possible recession. This was the first inversion since 2007 and served to spook already wary investors.

The second factor was the contradictions from the White House on the exact nature of the trade deal with China that President Trump had touted this weekend. These differing reports led many to believe that the deal may not be as solid as the president had made it seem. Basically fear crept back into the markets prior to tomorrow’s closure of the markets in honor of George H. W. Bush.

Jim Tierney, with Alliance Bernstein sees a very bleak future as quite possible if Trump isn’t able to assure investor’s that the trade tensions are under control. “If we have a trade problem, I think that risks bringing a number of developing economies to the brink of recession. It also puts a huge tax of U.S. consumers, and the combination of those two means a pretty meaningful global slowdown, which would indicate that right now the yield curve is correct in terms of where we’re going,” Tierney noted.

One might also point to the selloff being due in part to the unsettling nature of a Wednesday market closing with all outstanding aforementioned issues directly related to the US unresolved and the worldwide issue of the Brexit situation. The fear surrounding the market was too much for many to handle…understandably so.

Tomorrow will provide a break from today’s turmoil as the market is closing in honor of deceased President George H.W. Bush’s funeral. Rest in peace President Bush.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

Stocks nosedive, Dow sheds nearly 800 points

Stocks tanked Tuesday as a slew of concerns over trade tensions and an inversion in part of the U.S. yield curve spooked investors…

finance.yahoo.com

Read Full Article



Markets React Well to Atossa Genetics (ATOS) Announcing FDA Approval For “Expanded Access”

Atossa Genetics Inc., (NasdaqCM; ATOS) is a Seattle-based clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. ATOS announced on Monday that the FDA has approved an “expanded access” of Atossa’s proprietary oral Endoxifen in the preoperative setting in a U.S. patient awaiting surgery for breast cancer. Under the FDA Expanded Access IND program, the use of Atossa’s proprietary Endoxifen is restricted to this patient only.

The markets reacted positively to this news on Monday as ATOS shot up over 50% and hit a high of $1.85 while trading north of 16.8 million shares or approximately $28-30 million dollars of trading before closing at $1.38.

Note that Atossa is currently conducting a Phase 2 study of its oral Endoxifen in Australia in the “window of opportunity” between diagnosis of breast cancer and surgery.  Steven C. Quay, Ph.D., MD, President and CEO stated. “Once a patient is diagnosed with breast cancer, there is a window of time, typically a few weeks, before surgery is performed. Our goal with this study is to show that our proprietary oral Endoxifen can modify the cancer activity in ER+ breast cancer during this ‘window of opportunity.’ Because our Phase 1 study indicated that our oral Endoxifen reaches therapeutic levels within 8 hours and therapeutic steady-state levels in only seven days, we are optimistic we can achieve a valuable treatment effect.”

The Pilot Phase of the study will initially enroll up to eight newly-diagnosed patients with ER+ and HER2 negative (HER2-) stage 1 or 2 invasive breast cancer, requiring mastectomy or lumpectomy. Patients will receive Atossa’s proprietary oral Endoxifen for at least 21 days from the time of diagnosis up to the day of surgery. Provided tumor activity reduction is demonstrated in at least two patients, an additional 17 patients will be enrolled for a total of 25. The primary endpoint is to determine if the administration of oral Endoxifen reduces the tumor activity as measured by Ki-67, which is a marker of cellular proliferation. The secondary endpoints are safety and tolerability and assessment of the study drug on expression levels of both estrogen and progesterone receptors. The impact on additional markers of cellular activity will also be explored. The Phase 2 study is being conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia. CPR Pharma recently completed the successful Phase 1 study of Atossa’s oral and topical Endoxifen in women.

Steven C. Quay, Ph.D., MD, President and CEO commented further, “A physician recently contacted Atossa and requested our proprietary oral Endoxifen for a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient awaiting surgery. In this setting, the recommended preoperative endocrine systemic therapy is typically an aromatase inhibitor and a drug for ovarian suppression. The patient’s physician was reluctant to use this preoperative therapy as it typically induces menopause and can have other potentially serious side effects. We worked with the physician to apply to the FDA to provide “expanded access” (formerly known as compassionate use) to this patient under an Investigational New Drug (IND) application. We are very pleased to report that the FDA approved this single-patient study, and the patient is currently receiving our proprietary oral Endoxifen preoperatively. This is the same clinical setting as our Phase 2 ‘window of opportunity’ study of preoperative systemic oral Endoxifen in breast cancer patients which is open for enrollment in Australia.”

Note that expanded access, sometimes called “compassionate use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. Expanded access may be appropriate when all the following apply: patient has a serious disease or condition, or whose life is immediately threatened by their disease or condition; there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; patient enrollment in a clinical trial is not possible; potential patient benefit justifies the potential risks of treatment; providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication. Investigational drugs, biologics or medical devices have not yet been approved or cleared by FDA and FDA has not found these products to be safe and effective for their specific use. Furthermore, the investigational medical product may, or may not, be effective in the treatment of the condition, and use of the product may cause unexpected serious side effects. For more information, see the FDA website: FDA Expanded Use Website

If you found this story interesting you should consider following Atossa Genetics (Nasdaq: ATOS)  please see Atossa the dedicated coverage page at Vista Partners to learn more.

Atossa Genetics Announces FDA Approval of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient

Steven C. Quay, Ph.D., MD, President and CEO commented, “A physician recently contacted Atossa and requested our proprietary oral Endoxifen for a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient awaiting surgery. In this setting, the recommended preoperative endocrine systemic..

finance.yahoo.com

Read Full Article



“The Good & The Bad” – Vista Partners Daily Market Recap 12/3/2018

The good news is that stocks rallied on Monday as investors optimistic about reduced trade tensions with China after President Trump announced a 90-day cease fire in the trade war as negotiations continue. S&P 500 ended the session up 1.09% and the Nasdaq rose 1.51%. The Dow closed out the day with gains of 1.13%.

Most individual components of the Dow did well today, although some did dip into the red. Of those companies with losses, Verizon (VZ) had the most significant as it tumbled 3.55%. Boeing (BA) led the day with gains, rising 3.81%, and NIKE (NKE) wasn’t far behind with an increase of 3.75%

Atossa Genetics (ATOS) had a VERY good day as it saw shares spike 21.05% into the close on over 16.8 million shares of trading after hitting intraday highs that pushed the stock up over 50% at times. Note that ATOS is a Seattle based clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. The action in ATOS surfaced after the they announced that the FDA had approved an “expanded access” of Atossa’s proprietary oral Endoxifen in the preoperative setting in a U.S. patient awaiting surgery for breast cancer.

The bad news for the markets today though, came from an ominous sign in the bond market. For the first time since 2007, there was an inversion in Treasury yields. This inversion is a tell-tale sign that the market is typically headed toward recession and that there is a greater risk of the government defaulting.

While the major inversion that analysts look for to herald a recession is between the 2-year and 10-year yields, today’s was between the 3-year and 5-year yields.

Ian Lyngen, with BMO Captial Markets, stated that today’s inversion gives him even more reason to believe that there will be an inversion of the 2-year and 10-year yields late this year or in the early part of next year. According to Lyngen, “This solidifies not only my flattening bias but I think it will lead many players in the market who [expected the yield curve to steepen] to capitulate on that.”

Another negative sign came as U.S. construction spending was reported to have decreased by 0.1% in October. This is the 3rd consecutive month of decreases for construction spending in the U.S.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Stocks give up some gains after trade talk advances

Stocks pared some gains after optimism for a trade war truce between the U.S. and China had sent equities soaring earlier during Monday’s session…

finance.yahoo.com

Read Full Article



“Vista’s View – A Weekly FREE Market Update 12-1-18″…Now Available!

Vista Partners has published “Vista’s View – A Weekly Market Update Newsletter 12-1-18!”  Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink.   Vista’s View includes an exclusive view on the stock market for the week, a “Stocks To Watch” section, featured stories that span from the Dow 30, select emerging growth companies, investing basics & exciting videos from Vista’s Coverage Universe and beyond.

Vista Covers all Dow 30 components, International Companies, Select Emerging Growth Companies & more on the website daily.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page Now.  It’s FREE!!!

Stay Informed! Stay Competitive!  Receive our FREE emial updates by signing up today in just  few seconds!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




“Uncertain, But Rising” – Vista Partners Daily Market Recap 11/30/2018

US stocks were somewhat uncertain on Friday but ended the day rising. All three of the major indexes ended the day with gains. The S&P 500 rose 0.82% (22.41 points), and the Nasdaq increased 0.79% (57.45 points). The Dow also gained 0.79% (199.62 points) by the end of the session. This week’s gains for the S&P 500 mark the strongest week the index has had since December 2011.

Most components of the Dow saw gains today, although some weren’t so lucky. Goldman Sachs (GS) stood out with the biggest losses as it slipped 2.13% as it continues to deal with the ongoing potential negative scenarios related to 1MDB as the Malaysian government has sought refunds for fees paid the bank. Caterpillar (CAT), though, had a very nice day as it saw shares increase 4.18% by market close. Intel (INTC) also had substantial gains as it rose 3.38%.

Outside the Dow, Atossa Genetics (ATOS) ended the day just in the red with a loss of 0.87% for the day.

With oil seeing its largest losses in 10 years this month and the trade relationship with China still tense, all eyes are on the G20 summit meeting in Buenos Aires this weekend. President Trump and Chinese President Xi are set to have dinner on Saturday to discuss the trade war and hopefully come to some sort of agreement. Robert Lighthizer, a US Trade Representative, spoke to reporters and said that he’d “be very surprised if the dinner was not a success.” We are not so convinced….

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Stocks climb, investors brace for trade talks

Stocks rose as investors await a meeting between President Donald Trump and China’s President Xi Jinping, which will help shed light on the direction of future trade policy…

finance.yahoo.com

Read Full Article



“Close, But No Cigar” – Vista Partners Daily Market Recap 11/29/2018

US stocks had a choppy day of trading on Thursday with all three major indices nearly ending with gains but winding up just barely in the red instead. The S&P 500 slipped 0.22% (5.99 points) and the Nasdaq fell 0.25% (18.51 points). The Dow was just under for the day with a loss of 0.11% (27.59 points).

Individual components of the Dow were all over the board today with some seeing substantial gains and others facing losses. Boeing (BA) did well as it rose 2.72% and Pfizer (PFE) also ended the session up with an increase of 1.36%. On the flip side, Intel (INTC) saw shares slide 2.37%.

Atossa Genetics (ATOS) saw a loss of 3.36% for the day after significant increases during Wednesday’s session.

The Markets are facing many significant risks that have increased the volatility and could add to a downward moving market.  A few of the market disrupters include:  rising interest rates, unsettled white house affairs with China that involves wider or at least increased tariffs on China heading into the G20 summit &  the fact that oil prices continue to plummet after hitting a 4-yr high north of $76 to today’s range of $49.47 – $52.20 while closing at $51.26.

Some ominous news also came from the housing market today as it was reported that pending home sales had dropped 2.6% from September to October coming in at the lowest level in 4 years. The West was the hardest hit region with sales falling a whopping 8.9%.

According to Stephen Stanley, an economist at Amherst Pierpont Securities, “By all accounts, we are seeing a buyers’ strike this year, as prospective home buyers have tired of surging home prices, frenzied bidding on scarce homes for sale and most recently rising mortgage rates.”

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Stocks snap three-days winning streak, trade talks loom

Stocks fell Thursday ahead of a highly anticipated meeting between President Donald Trump and China’s President Xi Jinping at the G20 summit in Argentina…

finance.yahoo.com

Read Full Article



“Spikes & Speeches” – Vista Partners Daily Market Recap 11/28/2018

After the Fed’s stability report and Chairman Jerome Powell’s speech on the current state of the economy, US stocks opened higher and then spiked to end the day on Wednesday. The S&P 500 shot up 2.30% (61.61 points) and the Nasdaq rose 2.95% (208.89 points). The Dow ended the day on a strong note with gains of 2.50% (617.70 points).

All but one of the Dow’s components saw shares rise today with Verizon’s (VZ) loss of 0.97% being the lone outlier. Caterpillar (CAT) did especially well as it rose 4.95% during the session. And Apple (AAPL), which has had some recent trouble, saw a nice increase of 3.85%.

Outside the Dow, Atossa Genetics (ATOS) also had a good day as it’s stock rose 2.59%.

The Federal Reserve Chairman Jerome Powell seems to have told investors largely what they wanted to hear today in his speech given after the Fed’s release of a report detailing the financial risks facing the United States. After a month of volatility following a speech where Powell said that achieving neutral interest rates was “a long way off,” today the chairman had a much more welcome message. He noted, “Interest rates are still low by historical standards, and they remain just below the broad range of estimates of the level that would be neutral for the economy.”

The Fed’s report also seems to have helped to ease investors worries. In it, the central bank noted that there were several financial risks facing the United States including trade tensions, a possibly messy Brexit transition, and our relationship with China. Despite these potential trouble areas, the Fed insisted that risks should still be considered mild. In his speech, Powell clarified that “overall financial stability vulnerabilities are at a moderate level…The risks of destabilizing runs are far lower than in the past. The institutions at the heart of the financial system are more resilient.”

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Stocks spike, Powell says rates ‘just below’ neutral

Stocks rallied following a speech from Fed Chair Jerome Powell, which will provide further hints at the direction of future monetary policy in the wake of more than a month of turbulent equity trading. ..

finance.yahoo.com

Read Full Article